BRIEF RESEARCH REPORT
Published on 17 May 2024
Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
doi 10.3389/fonc.2024.1352281
- 1,915 views
- 1 citation
- Frontiers in Oncology
- Hematologic Malignancies
- Research Topics
- Novel Agents for Multiple Myeloma Vol. II
Novel Agents for Multiple Myeloma Vol. II
4,056
Total downloads
13k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Published on 18 Mar 2024
Prognostic significance of β2-microglobulin decline index in multiple myeloma
doi 10.3389/fonc.2024.1322680
- 1,080 views
REVIEW
Published on 04 Mar 2024
Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
doi 10.3389/fphar.2024.1351565
- 1,444 views
SYSTEMATIC REVIEW
Published on 28 Feb 2024
Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials
doi 10.3389/fimmu.2024.1348955
- 2,931 views
- 2 citations
SYSTEMATIC REVIEW
Published on 25 Jan 2024
Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review
doi 10.3389/fonc.2024.1286029
- 2,267 views
- 2 citations
BRIEF RESEARCH REPORT
Published on 06 Dec 2023
Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma
doi 10.3389/fonc.2023.1271847
- 1,551 views
- 1 citation
Published in
Frontiers in Oncology
- Hematologic Malignancies
- Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Pharmacology
- 4.4 impact factor
- 7.8 citescore
Impact
- 13kTopic views
- 8,821Article views
- 4,056Article downloads